Condition: Metastatic Castrate-Resistant Prostate Cancer (mCRPC) · Sponsor: Institute of Cancer Research, United Kingdom
ASpiRE will investigate the effect of the drug SX-682 in combination with Apalutamide in men suffering from metastatic castration-resistant prostate cancer (mCRPC).
This description comes directly from the study's public registry record.
Aasia Hussain, PhD · 02034376301 · ASPIRE@icr.ac.uk
Bindumalini Rao Baikady, PhD · 02034376033 · ASPIRE@icr.ac.uk
Always discuss trial participation with your own doctor first.
| Oncology Institute of Southern Switzerland | Bellinzona, Switzerland | Not Yet Recruiting |
| Belfast Health and Social Care Trust | Belfast, United Kingdom | Recruiting |
| Cambridge University Hospitals NHS Foundation Trust | Cambridge, United Kingdom | Recruiting |
| The Royal Marsden NHS Foundation Trust - Drug Development Unit | Sutton, United Kingdom | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07002320